Compare MLKN & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLKN | PHAT |
|---|---|---|
| Founded | 1905 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 894.0M |
| IPO Year | 1994 | 2019 |
| Metric | MLKN | PHAT |
|---|---|---|
| Price | $17.35 | $11.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.83 |
| AVG Volume (30 Days) | ★ 1.1M | 1.0M |
| Earning Date | 03-25-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.31% | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $3,669,900,000.00 | $175,110,000.00 |
| Revenue This Year | $5.94 | $93.04 |
| Revenue Next Year | $3.78 | $58.91 |
| P/E Ratio | $17.77 | ★ N/A |
| Revenue Growth | 1.14 | ★ 216.93 |
| 52 Week Low | $13.77 | $2.21 |
| 52 Week High | $23.18 | $18.31 |
| Indicator | MLKN | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 55.61 | 46.67 |
| Support Level | $16.55 | $11.04 |
| Resistance Level | $17.77 | $12.25 |
| Average True Range (ATR) | 0.60 | 0.69 |
| MACD | 0.45 | 0.07 |
| Stochastic Oscillator | 81.70 | 31.76 |
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.